Outpatient Oncology Infusion Market Players:
- Baxter International Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- B. Braun Melsungen AG
- Becton, Dickinson and Company
- Fresenius Kabi
- ICU Medical, Inc
- IRadimed Corporation
- Teleflex Medical Pvt. Ltd.
- Smiths Medical, Inc.
- Medtronic plc
Numerous important companies in the outpatient oncology infusion market are starting several tactical projects to increase their market share and strengthen their positions in the industry. It is predicted that the top five companies will control the majority of the outpatient oncology infusion market share by taking calculated risks, expanding, forming agreements, and participating in joint ventures.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of outpatient oncology infusion is evaluated at USD 8.14 billion.
The global outpatient oncology infusion market size was worth over USD 7.52 billion in 2025 and is poised to witness a CAGR of around 9.2%, crossing USD 18.13 billion revenue by 2035.
The North America outpatient oncology infusion market is anticipated to capture 37% share by 2035, driven by the expanding outpatient care industry and advanced healthcare infrastructure.
Key players in the market include B. Braun Melsungen AG, Becton, Dickinson and Company, Fresenius Kabi, ICU Medical, Inc., IRadimed Corporation, Teleflex Medical Pvt. Ltd., Smiths Medical, Inc., Medtronic plc.
